Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01899339 · ClinicalTrials.gov registry record
Long Term Effects of Treating Submassive Pulmonary Embolism With Ultra-sound Accelerated Thrombolysis
A clinical trial, sponsored by Corewell Health West.
- Completed
- Registry status
- 25
- Enrollment target
NCT01899339: Completed study, sponsored by Corewell Health West.
NCT01899339 is a clinical trial that has completed, run by Corewell Health West. The registered enrollment target is 25 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01899339 has completed, sponsored by Corewell Health West.
- COMPLETED
- Registry status
- 25 participants
- Enrollment target
Study Summary
Patients with Submassive Pulmonary Embolism treated with ultra-sound therapy will have an improved right ventricular function 72 hours post treatment.
Primary Outcome
Treatment will show improved Right Ventricular:Left Ventricular ratio at 72 hours post.
Interventions
- OTHER submassive PA treatment with Ekosonic endo device
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2013-05 |
| Est. Completion | 2019-02 |
What the finished NCT01899339 record still lists
NCT01899339 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 25 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which submassive PA treatment with Ekosonic endo device is the first listed.
NCT01899339 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01899339 about?
NCT01899339 is a clinical study titled "Long Term Effects of Treating Submassive Pulmonary Embolism With Ultra-sound Accelerated Thrombolysis". Patients with Submassive Pulmonary Embolism treated with ultra-sound therapy will have an improved right ventricular function 72 hours post treatment.
What is the current status of trial NCT01899339?
This trial is currently completed. The enrollment target is 25 participants. The study started on 2013-05. Estimated completion is 2019-02.
What interventions are being tested in trial NCT01899339?
The interventions under investigation include: submassive PA treatment with Ekosonic endo device (OTHER).
Who is sponsoring clinical trial NCT01899339?
This trial is sponsored by Corewell Health West, which has 38 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01166854 · 25 participants
Characterization of Familial Myopathy and Paget Disease of Bone
- NCT01913106 · 25 participants · Phase 1
HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer
- NCT02138669 · 25 participants · NA
Intacs Prescription Inserts for Keratoconus Patients
- NCT02174549 · 25 participants · Phase 1
Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia